Cargando…
EDP-M plus sintilimab in the treatment of adrenocortical carcinoma: a case report
BACKGROUND: Adrenocortical carcinoma (ACC) is a rare malignancy occurring in the adrenal cortex characterized by its low incidence rate, aggressive tumor behavior with high propensity of invasion and distant metastasis, and poor prognosis. When detected, it usually appears as advanced tumor with lim...
Autores principales: | Zhang, Zhipeng, Liu, Ningning, Li, Qi |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
AME Publishing Company
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9273713/ https://www.ncbi.nlm.nih.gov/pubmed/35836542 http://dx.doi.org/10.21037/tcr-21-1993 |
Ejemplares similares
-
Efficacy of the EDP-M Scheme Plus Adjunctive Surgery in the Management of Patients with Advanced Adrenocortical Carcinoma: The Brescia Experience
por: Laganà, Marta, et al.
Publicado: (2020) -
Supportive therapies in patients with advanced adrenocortical carcinoma submitted to standard EDP-M regimen
por: Turla, Antonella, et al.
Publicado: (2022) -
ASXL1 promotes adrenocortical carcinoma and is associated with chemoresistance to EDP regimen
por: Wang, Liang, et al.
Publicado: (2021) -
Correction for: ASXL1 promotes adrenocortical carcinoma and is associated with chemoresistance to EDP regimen
por: Wang, Liang, et al.
Publicado: (2023) -
Sintilimab: Pneumonitis: case report
Publicado: (2021)